25 results about "Signaling proteins" patented technology

The present invention relates to a peptide having an activity of promoting hair growth or preventing or inhibiting hair loss. The peptide of the present invention has an activity of promoting proliferation of hair follicle dermal papilla cells (HFDPC), activating a cell proliferation-related signal protein in human dermal papilla cells, activating β-catenin, improving expression levels of factors downstream of β-catenin, down-regulating expression levels of hair-loss protein DKK-1, and increasing expression of keratins in hair outer root sheath cells (HORSC).

The present invention relates to a peptide with the activity of promoting hair growth or preventing or inhibiting alopecia. The peptide of the present invention promotes the proliferation of human follicular dermal papilla cells (HFDPC), activates cell proliferation-related signaling proteins and beta-catenin in human dermal papilla cells, enhances the expression levels of beta-catenin downstream genes, down-regulates the expression levels of the hair loss protein DKK-1, increases the expression of keratin proteins in hair outer root sheath cells (HORSC) and up-regulates the expression of transcription factors involved in cell activation in germinal matrix cells (GMC).

The present disclosure describes PLPC-DB, an ultrapure phospholipoproteomic composition consisting of essential phospholipids, bioactive proteins, and intercellular regulatory factors, derived from the supernatant of peripheral blood mononuclear cells (PBMCs). This composition achieves a purity level exceeding 99% through a patented purification process that integrates high-speed advanced centrifugation and selective ultrafiltration, ensuring the structural stability and functional integrity of its bioactive components. PLPC-DB is optimized for advanced research and diagnostic applications, providing reproducibility, consistency, and safety across multicenter studies. The essential biomolecular components of PLPC-DB include phosphatidylcholine and phosphatidylserine, which contribute to membrane stability and intracellular signaling, while cell communication peptides enhance intercellular signaling, homeostatic regulation, and biochemical coordination. Structural and regulatory lipids support cell membrane biogenesis and functional stability, whereas adhesion and signaling proteins mediate cell-cell interactions and immune response coordination. Additionally, bioactive regulatory factors modulate immune and inflammatory responses, contributing to tissue regeneration and metabolic homeostasis.

Provided herein is a composition comprising, a cell, comprising nucleic acids encoding a chimeric antigen receptor (CAR) and one or more of signaling proteins selected from K13-vFLIP, MC159-vFLIP, cFLIP-L, cFLIP-p22, HTLV1-Tax and HTLV2-Tax, wherein the CAR comprises an a) extracellular antigen specific domain, b) a transmembrane domain and c) an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM); wherein c) is located at the C-terminus of the chimeric receptor. In some embodiments, the CAR further comprises one or more co-stimulatory domains. Also provided herein are methods for treating diseases using the compositions described herein. Further provided herein is a kinase inhibitor for use in therapeutic methods described herein.

The invention relates to a signal protein RH1 for promoting phosphorus absorption and growth of plants and application of the signal protein RH1, the amino acid sequence of the signal protein RH1 is shown as SEQ ID NO.1, and the plants include but are not limited to arabidopsis thaliana and oilseed rape.

Provided herein is a transmembrane signaling protein comprising: (a) an extracellular binding domain comprising a scFv having the CDRs of a selected antibody, (b) a transmembrane domain, and (c) an intracellular signaling domain. Cells expressing the same are also provided, as well as methods of treatment that employ the same.

This invention discloses a method for constructing an immune animal model for preparing biofusion enzyme antibodies and its application. The method includes the following steps: designing and screening sgRNAs with high cleavage efficiency based on signal protein genes, and constructing an sgRNA-Cas9 expression vector; linearizing the plasmid by double enzyme digestion, and then ligating it with a signal protein gene fragment containing left and right homologous arms to obtain the Donor plasmid; co-transfecting the sgRNA-Cas9 expression vector and the Donor plasmid into target animal somatic cells, and screening to obtain positive somatic cells that stably integrate the target gene; using the positive somatic cells as nuclear donors for nuclear transfer to construct recombinant embryos, and transferring the recombinant embryos into recipient female animals; after delivery, identifying transgenic animal individuals carrying biofusion enzyme antibodies by genomic PCR. Based on this transgenic animal model, different target antibodies with clinical value can be developed.

The invention belongs to the technical field of gene engineering, and particularly relates to a light-controlled yeast two-hybrid system as well as an establishment method and application thereof. The light-controlled yeast two-hybrid system is obtained by integrating a phycocyanobilin synthesis module into a yeast strain containing a reporter gene and then transferring into a phytochrome A-LexA fusion expression vector and an AD-FHY1 fusion expression vector. The light-controlled yeast two-hybrid system provided by the invention well overcomes the defects that the existing light-controlled yeast two-hybrid system needs exogenous application of phycocyanobilin, the operation is more complex and the cost is higher, and does not cause that the phytochrome apoprotein expressed in yeast cells cannot realize conversion of two conformational forms of Pfr / Pr; and finally, the difference between the interaction intensity of the phytochrome in two conformational forms and the FHY1 signal protein cannot be distinguished.

Biodegradable particles for interacting with immune cells to generate an immunosuppressive effect are disclosed. The biodegradable particle comprises a polyester or polyester blend with at least one soluble protein or small molecule encapsulated within the particle and at least two types of protein attached to a surface of the particle or to a coating on the surface thereof, which can be used to induce targeting regulatory T cells (Tregs). The at least two types of protein attached to a surface of the particle or to a coating on the surface thereof include a “Signal 1” protein that binds to an immune cell and a “Signal 2” protein that acts as a co-stimulatory molecule to immune cells. The encapsulated protein can be an interleukin and / or a cytokine. Methods of their use for treating a disease or condition, including an autoimmune disease, are disclosed.

The present disclosure relates to methods of treating pancreatic cancer. In particular, methods of treating pancreatic cancer and limiting overexpression of oncogenes, activating tumor suppressor genes, or modulating signaling proteins in a patient are described, comprising administering a compound and a pharmaceutical combination as described herein.

This invention relates to peptides with activity that promotes hair growth or prevents or inhibits hair loss. The peptides of this invention promote the proliferation of human follicular dermal papilla cells (HFDPC), activate cell proliferation-related signaling proteins and β-catenin in HFDPC, enhance the expression levels of downstream genes of β-catenin, downregulate the expression level of the hair loss protein DKK-1, increase the expression of keratin in hair follicle outer root sheath cells (HORSC), and upregulate the expression of transcription factors involved in cell activation in germinal stromal cells (GMC).

The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.

This invention relates to the field of biopharmaceuticals, and in particular to an Fc signaling protein and its uses. The Fc signaling protein is the Fc segment of an engineered IgG antibody or an engineered FcγRIIA. The engineered IgG antibody's Fc segment is obtained by mutating the Fc segment of a wild-type IgG antibody. When the engineered IgG antibody's Fc segment binds to FcγRIIA, the reverse bond interaction is stronger than when the wild-type FcγRIIA binds to the Fc segment of the IgG antibody. Similarly, the engineered FcγRIIA, obtained by mutating wild-type FcγRIIA, also exhibits a stronger reverse bond interaction when binding to the Fc segment of an IgG antibody than when the wild-type FcγRIIA binds to the Fc segment of the IgG antibody.

The present invention belongs to the field of pharmaceutical formulations. Specifically disclosed are a nanodrug for synergistically removing fibrosis and inhibiting pancreatic cancer metastasis and a preparation method therefor. By means of the self-assembly of a small-molecule prodrug, excipient-related toxicity is avoided, and a high drug loading rate is achieved. By means of hybrid membrane encapsulation, homologous targeting of fibrotic adhesion interstitium and receptor protein-mediated active targeting are achieved. By means of the response of the prodrug molecule to ROS, massive, rapid, and traceless drug release is achieved in the fibrotic adhesion interstitium, removing the self-limiting characteristic of the release of a responsive small-molecule drug. The released drugs Cap and CA can simultaneously inhibit fibrosis signals / proteins, synergistically removing fibrosis. As the removal of fibrosis progresses, Cap and CA released rapidly and tracelessly in pancreatic cancer cells can simultaneously inhibit the metastasis / invasion signaling pathway of pancreatic cancer cells, synergistically inhibiting metastasis. The dynamic synergy between the process of removing fibrosis and the process of inhibiting metastasis provides a new approach for removing fibrosis in the treatment of pancreatic cancer.

The invention discloses a Napsin A biological fusion enzyme antibody with a signal protein tag and application, an amino acid sequence of a light chain variable region of an anti-human Napsin A antibody is shown as SEQ ID NO: 7, an amino acid sequence of a heavy chain variable region of the anti-human Napsin A antibody is shown as SEQ ID NO: 3, the signal protein tag HRP is inserted into the N end of a light chain of the anti-human Napsin A antibody, and the amino acid sequence of the light chain variable region of the obtained HRP-Napsin A antibody is shown as SEQ ID NO: 5. In addition, the invention also provides a preparation method of the HRP-Napsin A antibody, the HRP-Napsin A antibody is a molecule completely secreted along with the antibody, has no heterogeneity, is good in sensitivity, high in specificity and stable in performance, and does not need to add a secondary antibody during detection, so that the cost is saved, and the efficiency is improved.

The present disclosure describes PLPC-DB, an ultrapure phospholipoproteomic composition consisting of essential phospholipids, bioactive proteins, and intercellular regulatory factors, derived from the supernatant of peripheral blood mononuclear cells (PBMCs). This composition achieves a purity level exceeding 99% through a patented purification process that integrates high-speed advanced centrifugation and selective ultrafiltration, ensuring the structural stability and functional integrity of its bioactive components. PLPC-DB is optimized for advanced research and diagnostic applications, providing reproducibility, consistency, and safety across multicenter studies. The essential biomolecular components of PLPC-DB include phosphatidylcholine and phosphatidylserine, which contribute to membrane stability and intracellular signaling, while cell communication peptides enhance intercellular signaling, homeostatic regulation, and biochemical coordination. Structural and regulatory lipids support cell membrane biogenesis and functional stability, whereas adhesion and signaling proteins mediate cell-cell interactions and immune response coordination. Additionally, bioactive regulatory factors modulate immune and inflammatory responses, contributing to tissue regeneration and metabolic homeostasis.

The invention belongs to the technical field of biocontrol microorganism genetic engineering, and particularly relates to an sfgA gene for regulating and controlling growth and development of beauveria bassiana and application of the sfgA gene. The invention discloses an sfgA gene for regulating and controlling growth and development of beauveria bassiana, the nucleotide sequence of the sfgA gene is as shown in SEQ ID NO.1, and the amino acid sequence of encoded protein of the sfgA gene is as shown in SEQ ID NO.2. By systematically researching the effect of the development signal protein sfgA in the asexual spore production process of the beauveria bassiana and the regulation and control mechanism of the development signal protein sfgA, the growth and development of the beauveria bassiana can be regulated and controlled. A theoretical basis is laid for researching a filamentous fungus asexual sporulation molecular mechanism, and a new scientific basis and gene resources are provided for mining and genetic improvement of biocontrol potentials of biocontrol fungi.

This invention relates to the field of *Paenibacillus polymyxa*, addressing the problem of low production of immune signaling proteins in existing *Paenibacillus* strains. It provides a new *Paenibacillus polymyxa* strain, deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC NO.36323. This invention provides a novel *Paenibacillus* strain that possesses both high production of immune signaling proteins and natural biocontrol and growth-promoting properties. It can secrete polymyxin-like antibacterial substances and simultaneously synthesize PR proteins and selenomethionine, overcoming the limitations of traditional *Paenibacillus* strains that only inhibit bacterial growth and lack immune signal transduction. The preparation method provided by this invention involves the strain converting sodium selenite into nano-selenium, which combines with the secreted PR protein to form nano-selenoprotein. Simultaneously, it synergistically produces polymyxins, achieving a dual effect of immune signal activation and direct bacterial inhibition, solving the problems of weak signaling and lack of synergistic antibacterial effects of traditional inducers.

The invention relates to a peptide capable of promoting hair growth and preventing and inhibiting alopecia and application thereof. The peptide provided by the invention has the following activities: promoting proliferation of hair follicle dermal papilla cells (HFDPC), activating cell proliferation-related signaling proteins and beta-catenin in human dermal papilla cells, enhancing the expression level of growth factor-related genes, enhancing the expression level of beta-catenin downstream genes, reducing the expression level of alopecia protein DKK-1, and promoting the growth of the hair follicle dermal papilla cells. Increasing the expression of keratin in hair outer root sheath cells (HORSC), and increasing the expression of transcription factors involved in cell activation in hair growth stromal cells (GMC); and promoting differentiation of hair follicle stem cells (HFSC).

This invention relates to the fields of biotechnology and medicine, and particularly to nucleic acid aptamers, biosensors, and their applications. The invention provides nucleic acid aptamers having nucleotide sequences as shown in any of SEQ ID NO:1 to SEQ ID NO:14. The invention utilizes in vitro screening technology to screen nucleic acid aptamers, ultimately obtaining nucleic acid aptamers that target and bind to the ADAR1 protein. Subsequently, based on the nucleic acid aptamers as target protein recognition elements, a dual-signal protein biosensor with input and output signals is constructed, enabling in vitro detection of target proteins and imaging of native proteins in live cells. Finally, the imaging technology is applied to drug evaluation and screening of proteins.

The application discloses an anti-platelet GPIb-IX antibody and application thereof, and belongs to the technical field of biological medicines. The application selects the starting signal protein GPIb-IX of arterial thrombosis as a target, and prepares an anti-human GPIb-IX humanized antibody. Specifically, human platelets are used as antigens to immunize mice, and a mouse-derived anti-human GPIb-IX antibody is obtained through screening and preparation, a humanized anti-GPIb-IX antibody ATHA is constructed by mutating a human-derived sequence, the heavy chain variable region of the ATHA comprises a VH-CDR3 shown in SEQ ID NO. 1, and the light chain variable region comprises a VL-CDR3 shown in SEQ ID NO. 2. The Fab segment of the ATHA can effectively inhibit platelet activation mediated by the GPIb-IX receptor, inhibit thrombosis in the body without accompanying side effects such as platelet reduction and bleeding, and has the characteristics of high specificity, good safety and small side effects. Meanwhile, the ATHA can remove platelets. Therefore, the ATHA-Fab has clinical value as a new anti-thrombotic drug, and can be used for treating diseases related to arterial thrombosis. The ATHA can remove platelets, and can be used for treating diseases with increased platelet quantity or removing platelets in the body.

The present invention provides a novel antibody fragment based antifungal conjugate selectively targeting Candida spp. comprising of at least one antimicrobial peptide at one end of the conjugate, more particularly, human Histatin-5; an antibody fragment at the other end of the conjugate, specific against Candida spp. enolase, a virulence factor protease and biofilm specific antigen of Candida spp.; at least one signal protease cleavage sequence susceptible to cleavage by virulent protease secreted by Candida spp., secreted aspartyl proteinase-1 (SAP1); and at least one flexible polypeptide linker. The signal protease cleavage sequence and the flexible polypeptide linker are in tandem with each other and placed in between the antimicrobial peptide and the antibody. The in vitro MIC-99 of the conjugate against Candida spp., is in the range of 0.2-0.3 μM, more specifically, 0.25 μM or 250 nM.

The invention discloses a construction method and application of an immune animal model for preparing a biological fusion enzyme antibody, and the construction method comprises the following steps: according to a signal protein gene, designing and screening to obtain sgRNA with high cutting efficiency, and constructing an sgRNA-Cas9 expression vector; carrying out double enzyme digestion linearization on the plasmid, and carrying out enzyme linkage on the plasmid and a signal protein gene segment containing left and right homologous arms to obtain a Donor plasmid; co-transfecting the sgRNA-Cas9 expression vector and a Donor plasmid into a target animal somatic cell, and screening to obtain a positive somatic cell stably integrated with a target gene; taking the positive somatic cells as nuclear donors for nuclear transfer to construct recombinant embryos, transferring the recombinant embryos into receptor female animal bodies, and performing genome PCR (polymerase chain reaction) identification after delivery to obtain transgenic animal individuals carrying biological fusion enzyme antibodies. Based on the transgenic animal model, different target antibodies which are valuable in clinical application can be developed.

The peptide of the present invention has the activity of promoting the proliferation of hair follicle dermal papilla cells (HFDPC); the composition can be used for activating cell proliferation related signal transduction protein and beta-catenin, up-regulating the expression level of growth factor related genes, up-regulating the expression level of beta-catenin subgenes and down-regulating the expression level of alopecia protein DKK-1 in human dermal papilla cells; increasing the expression of keratin in hair outer root sheath cells (HORSC); enhancing expression of transcription factors involved in cell activation in HGMC (Hair Growth Matrix Cells); and promoting differentiation of hair follicle stem cells (HFSC). Therefore, the peptide of the present invention can be used to promote hair growth or to inhibit, prevent, alleviate or treat alopecia.

The invention relates to the technical field of biomedicine, in particular to a thalamus / interbrain organ and neuron culture method. The invention provides a method for efficiently differentiating thalamic / interbrain organs and neurons by using human embryonic stem cells or induced pluripotent stem cells. It is found that in the early stage of cell differentiation, the c-JUN gene plays an important role in promoting nerve maturation and maintaining tight junction, the growth rate and the size of thalamus / interbrain organs can be remarkably increased by overexpressing c-JUN or adding c-JUN protein in thalamus / interbrain differentiation, the obtained organs have high-abundance neurons and tight junction protein, and the cell differentiation effect is good. And high expression of thalamus / interbrain characteristic signal protein TCF7L2 is realized. The neurons have abundant nerve fibers and adherent growth ability under the 2D culture condition, and the lifetime is long. The invention provides an efficient 2D neuron and 3D organoid differentiation technology for researching related development and pathology of thalamus / interbrain.